Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy
| Autor: | Yasuyo Yamamoto, Shunsuke Furutani, Masatsugu Komori, Tomoharu Fukumori, Takashi Kawanaka, Hidehisa Mori, Yoshito Kusuhara, Tomoya Fukawa, Masayuki Takahashi, Junichiro Kagawa, Hiro-omi Kanayama, Hitoshi Ikushima, Akiko Kubo, Tomokazu Senzaki, Kunihisa Yamaguchi |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Diagnostic Imaging
Male Oncology medicine.medical_specialty Time Factors Biopsy Urology medicine.medical_treatment Brachytherapy Disease-Free Survival Prostate cancer Prostate Internal medicine medicine Humans Clinical significance Neoadjuvant therapy Aged Retrospective Studies Aged 80 and over Dose-Response Relationship Drug medicine.diagnostic_test business.industry Prostatic Neoplasms Androgen Antagonists Dose-Response Relationship Radiation Retrospective cohort study Middle Aged medicine.disease Neoadjuvant Therapy Treatment Outcome medicine.anatomical_structure business Prostate brachytherapy Follow-Up Studies |
| Zdroj: | Urologia Internationalis. 95:457-464 |
| ISSN: | 1423-0399 0042-1138 |
| DOI: | 10.1159/000439573 |
| Popis: | Introduction: The aim of this study is to clarify the clinical significance of neoadjuvant combined androgen blockade (CAB) for ≥6 months in patients with localized prostate cancer. Patients and Methods: A total of 431 patients with localized prostate cancer who underwent prostate brachytherapy (BT) with or without neoadjuvant CAB for ≥6 months with mean follow-up time of 64.6 months (range 24-108 months) were evaluated retrospectively. Of those 431, 232 patients received BT in combination with neoadjuvant CAB for ≥6 months. Biochemical recurrence-free rates (BRFRs) in 364 patients with at least 3 years of follow-up were evaluated by log-rank test. Results: BRFR in patients with low-, intermediate- and high-risk prostate cancer were 98.1, 94.2 and 89.1%, respectively. In patients with intermediate-risk prostate cancer only, neoadjuvant CAB was significantly associated with BRFR (p = 0.0468). Especially in patients with intermediate-risk prostate cancer with radiation dose received by 90% of the prostate (D90) Conclusions: Neoadjuvant CAB for ≥6 months has a favorable impact on BRFR in patients with intermediate-risk prostate cancer, particularly in patients with relatively low radiation doses of D90. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|